LDS/Medical Tests/Dopamine Receptor D4 (DRD4) Genotyping

Dopamine Receptor D4 (DRD4) Genotyping

The dopamine receptor D4 gene (DRD4) is highly polymorphic, located near the telomeric region of chromosome 11q, which encodes the D4 subtype of the dopamine receptor. The D4 subtype is a G-protein coupled receptor which inhibits adenylyl cyclase. Most common genetic mutations have been associated with various behavioral phenotypes, including autonomic nervous system dysfunction, attention deficit/hyperactivity disorder, and the personality trait of novelty seeking. This gene contains a polymorphic number (2–11 copies) of tandem 48-nt repeats in exon 3, creating a 32- to 176-amino acid variation in the third intracellular loop on the dopamine receptor. The polymorphism exists at two levels. At the higher level there is an imperfect tandem repeat of 48 base pairs (bp) coding for 16 amino acids; alleles have been identified with 2 (32 amino acids) to 10 (160 amino acids) repeats. The imperfect nature of the repeats is responsible for a more subtle level of variation since alleles with the same number of repeats can differ in the exact sequences or in the order of the variants of the 48-bp unit. The DRD4 7-repeat allele (7R) has functional consequences and is associated with lower affinity for dopamine receptor agonists and reduced signal transduction (e.g., cAMP levels) compared to the more common DRD4 4-repeat allele (4R). The effect of other copy number repeats remains unclear. Allele frequencies differ considerably between different populations. The 4-repeat allele is the most prevalent (global mean allele frequency, 64.3%) and appears in every tested population with a frequency ranging from 0.16 to 0.96. The 7-repeat allele is the second most common (global mean, 20.6%), appearing quite frequently in the Americas (mf 48.3%) but only occasionally in East and South Asia (mf 1.9%). The 2-repeat allele is the third most common (global mf, 8.2%) and is quite frequent in East and South Asia (mf, 18.1%) and uncommon in the Americas (mf, 2.9%) and Africa (mf, 1.7%). Allele/Number of repeats (R) Allelic Frequency (%) 2R 8.8 3R 2.4 4R 65.1 5R 1.6 6R 2.2 7R 19.2 8R 0.6 9R <0.1 10R <0.1 11R <0.1
  • Influencing the target dose of methylphenidate treatment for patients with attention deficit hyperactivity disorder
  • Determining possible cause for poor response to methylphenidate in treated patients with attention deficit/hyperactivity disorder

The presence of the DRD4 7R allele, alone or in combination with the SLC6A4 long/long promotor polymorphism of the serotonin transporter, is associated with lower responsiveness of ADHD to methylphenidate (e.g., Ritalin, Concerta), the main treatment for ADHD. Methylphenidate dosage may have to be increased to effectively treat individuals with the DRD4 7R allele.

The effect of other repeat numbers has not been defined and, if other alleles than the 4R and 7R are present, caution should be exercised in using methylphenidate to treat ADHD because the impact of these alleles on treatment response is not known.

Attempts to find an association between DRD4 genotype and the variability of response to antipsychotic drugs, especially clozapine, have been largely unsuccessful or have yielded conflicting results.

Genotypes are reported as the number of repeat copies per allele. The 4-repeat allele is considered wild-type (4R/4R)

Polymerase chain reaction followed by agarose gel electrophoresis for fragment analysis; real-time PCR with allele specific primer extension or ARMS; conventional sequencing; next-generation sequencing.

Whole blood (EDTA), Saliva, Or Buccal swab. 

 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Serotonin, dopamine, and catecholamine levels, Catechol-O-methyltransferase Genotyping (COMT), Drug monitoring.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login